Valuation: Intellipharmaceutics International Inc.

Market Cap 14.06L 12.37L 11.66L 10.64L 19.9L 14Cr 20.05L 1.4Cr 54.23L 6.87Cr 52.81L 51.66L 22Cr P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 36.49L 32.09L 30.25L 27.6L 51.62L 35Cr 52.02L 3.63Cr 1.41Cr 18Cr 1.37Cr 1.34Cr 58Cr EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 01/04/2007
Corporate Officer/Principal - 01/02/2014
Director TitleAgeSince
Director/Board Member - 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-11.11% - - 33
+2.68%+2.56%+59.32%+114.68% 1,02600Cr
+0.56%+0.17%+53.19%+68.65% 65TCr
+0.02%+0.42%+20.51%+73.58% 47TCr
+0.06%+0.61%+39.82%+45.71% 35TCr
+1.16%+2.53%+21.60%+29.39% 27TCr
-0.24%-0.23%+10.62%+12.26% 26TCr
-0.01%+6.91%+45.42%+51.68% 22TCr
-1.11%-0.80%+31.69%+99.56% 19TCr
+0.30%-9.43%-31.91%-60.56% 17TCr
Average +0.07%+0.52%+27.81%+48.33% 39.99TCr
Weighted average by Cap. +0.12%+1.06%+38.36%+67.68%

Financials

2021 2022
Net sales - 65.73T 57.81T 54.5T 49.72T 92.99T 63.09L 93.71T 7L 3L 32.11L 2L 2L 1.04Cr
Net income -51.45L -45.26L -42.66L -38.92L -72.79L -49Cr -73.36L -5.12Cr -1.98Cr -25Cr -1.93Cr -1.89Cr -82Cr -28.92L -25.44L -23.98L -21.88L -40.92L -28Cr -41.24L -2.88Cr -1.12Cr -14Cr -1.09Cr -1.06Cr -46Cr
Net Debt 11.45L 10.08L 9L 9L 16.21L 11Cr 16.33L 1.14Cr 44.17L 5.6Cr 43.01L 42.07L 18Cr 22.42L 19.72L 18.59L 16.96L 31.72L 22Cr 31.97L 2.23Cr 86.46L 11Cr 84.19L 82.36L 36Cr
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11